Ex vivo assessment of immunosuppression in undiluted whole blood from pigs dosed with tacrolimus (FK506)

被引:2
|
作者
Chen, YW [1 ]
Smith, ML [1 ]
Sheets, MP [1 ]
Ballaron, SJ [1 ]
Trevillyan, JM [1 ]
Fey, TA [1 ]
Gauvin, DM [1 ]
Kolano, R [1 ]
Pong, MS [1 ]
Hsieh, GC [1 ]
Bauch, J [1 ]
Marsh, K [1 ]
Carter, G [1 ]
Luly, J [1 ]
Djuric, S [1 ]
Mollison, KW [1 ]
机构
[1] Abbott Labs, Immunol Dis Res, Abbott Pk, IL 60064 USA
关键词
ex vivo; immunosuppression; FK506; pigs; IL-2;
D O I
10.1006/clim.1998.4625
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To assess the duration of immunosuppression in FK506-dosed pigs, an undiluted whole blood assay was established to measure reactivities of T cells in their physiological milieu. PMA and ionomycin were shown to induce IL-2 production in swine blood. The IC50 of FK506 in inhibiting IL-2 production in whole blood and isolated PBMC stimulated with PMA and ionomycin measured 1.2 and 0.04 nM, respectively. These data underscore the influence of red blood cells and plasma proteins on drug potency. IL-2 levels were determined in blood drawn immediately before and 1, 24, 48, and 72 h after iv dosing. For pigs dosed with 0.05 mg/kg, 50% recovery of IL-2 production was observed at 16 h and 100% at 35 h after dosing. For pigs dosed with 0.15 mg/kg; 50% recovery was observed at 38 h and 100% at 72 h. Blood concentrations of FK506 at 50 and 100% recovery of IL-2 production measured 10.8 and 2.2 nM for pigs dosed with 0.05 mg/kg and 6.1 and 1.1 nM:for pigs dosed with 0.15 mg/kg, respectively. These concentrations are severalfold higher than predicted from the IC,, of FK506 for inhibiting IL-2 production in the whole blood assay. These data suggest that the true potency of FK506 in blood after dosing is influenced by additional factors, which could include plasma protein binding, the presence of active or interfering metabolites, serum interfering factors, and sequestration of drug in blood cells. Our results demonstrate the utility of an undiluted whole blood assay for assessing the duration of immunosuppression in drug-dosed animals and emphasize the importance of assessing drug potency in the whole blood environment ex vivo. (C) 1999 Academic Press.
引用
收藏
页码:133 / 140
页数:8
相关论文
共 50 条
  • [21] Rapid trabecular bone loss after cardiac transplantation using FK506 (tacrolimus)-based immunosuppression
    Stempfle, HU
    Werner, C
    Echtler, S
    Assum, T
    Meiser, B
    Angermann, CE
    Theisen, K
    Gärtner, R
    TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) : 1132 - 1133
  • [22] TACROLIMUS (FK506) VERSUS CYCLOSPORINE AS PRIMARY IMMUNOSUPPRESSION FOLLOWING TRANSPLANTATION FOR FULMINANT HEPATIC-FAILURE
    DEVLIN, J
    WILLIAMS, R
    HEPATOLOGY, 1995, 22 (04) : 149 - 149
  • [23] Tacrolimus (FK506) versus cyclosporine microemulsion (Neoral) as maintenance immunosuppression therapy in kidney transplant recipients
    Abou-Jaoude, MM
    Najm, R
    Shaheen, J
    Nawfal, N
    Abboud, S
    AlHabash, M
    Darwish, M
    Mulhem, A
    Ojjeh, A
    Almawi, WY
    TRANSPLANTATION PROCEEDINGS, 2005, 37 (07) : 3025 - 3028
  • [24] Conversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantation
    Lipson, DA
    Palevsky, HI
    Kotloff, RM
    Edelman, J
    TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) : 1505 - 1507
  • [25] Tacrolimus (FK 506): A whole blood assay as measured on the Abbott IMx analyzer
    McKenna, BA
    Pabico, RC
    Bronsther, OL
    Morris, MC
    Orloff, MS
    Erturk, E
    TRANSPLANTATION PROCEEDINGS, 1996, 28 (02) : 988 - 990
  • [26] In vitro-in vivo extrapolations to evaluate the effect of concomitant drugs on tacrolimus (FK506) exposure
    Oda, Kazuo
    Yamano, Katsuhiro
    Otsuka, Yukio
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2015, 36 (05) : 265 - 274
  • [27] Cyclosporin A and tacrolimus (FK506) differentially alter T-cell receptor expression in vivo
    Miller, Jamie Leigh
    Ericson, Solveig Gronning
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2007, 29 (01) : 105 - 118
  • [28] THE EFFECT OF FLUCONAZOLE ON TACROLIMUS (FK506) BLOOD-LEVELS IN RENAL-TRANSPLANT RECIPIENTS
    HARIHARAN, S
    SCHLUETER, K
    PEDDI, VR
    SCHROEDER, TJ
    FIRST, MR
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1995, 6 (03): : 1090 - 1090
  • [29] In Vitro and In Vivo Assessment of FK506 Analogs as Novel Antifungal Drug Candidates
    Lee, Yeonseon
    Lee, Kyung-Tae
    Lee, Soo Jung
    Beom, Ji Yoon
    Hwangbo, Areum
    Jung, Jin A.
    Song, Myoung Chong
    Yoo, Young Ji
    Kang, Sang Hyeon
    Averette, Anna F.
    Heitman, Joseph
    Yoon, Yeo Joon
    Cheong, Eunji
    Bahn, Yong-Sun
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (11)
  • [30] CARDIOVASCULAR CONSEQUENCES OF IMMUNOSUPPRESSION IN RATS - EFFECT OF FK506 ON BLOOD-PRESSURE (BP) REACTIVITY
    ROULLET, JB
    PHANOUVONG, T
    ANDOH, TF
    MCCARRON, DA
    BENNETT, WM
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1995, 6 (03): : 1064 - 1064